Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT05079282
Trial Phases:	Phase I	Protocol IDs:	ONO-4685-03 (primary) NCI-2022-03223
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Ono Pharmaceutical Company Limited
NCI Full Details:	http://clinicaltrials.gov/show/NCT05079282

Summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary
efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.